RHON-KLINIKUM AG (RHK) AI Stock Analysis

• Market Cap: €756.40M
• Dividend Yield: 0.76%
• Average Volume (3M): 2.79K
• Price to Earnings (P/E): 19.7
• Beta (1Y): 0.03
• Revenue Growth: 12.23%
• EPS Growth: -8.23%
• Country: DE
• Employees: 18,819
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Care Facilities
• EPS (TTM): 0.11
• Shares Outstanding: 66,962,470
• 10 Day Avg. Volume: 5,216
• 30 Day Avg. Volume: 2,794
• PEG Ratio: -2.47
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: €13.00 ▲(9.24%Upside)

Rhon-Klinikum AG's overall score is boosted by its strong financial performance, especially its solid balance sheet and cash flow management. However, the stock faces challenges with bearish technical indicators and a potentially high valuation, which weigh down its score.

RHON-KLINIKUM AG Business Overview & Revenue Model

Company Description

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. It operates eight hospitals and 5,420 beds/places at five medical sites. The company is based in Bad Neustadt an der Saale, Germany.

How the Company Makes Money

RHÖN-KLINIKUM AG primarily generates revenue through the provision of healthcare services. This includes income from inpatient and outpatient care, surgical procedures, diagnostic services, and rehabilitation programs. The company receives payments from a variety of sources, including public and private health insurance providers, government healthcare programs, and direct patient payments. Additionally, RHÖN-KLINIKUM AG may engage in partnerships with other healthcare organizations, research institutions, and technology providers to enhance its service offerings and operational efficiency, contributing to its revenue streams.

RHON-KLINIKUM AG Financial Statement Overview

Summary

RHON-KLINIKUM AG exhibits solid financial health with a strong balance sheet and cash flow management. The income statement shows stable margins, although revenue growth has been uneven. The company maintains a strong equity position, low leverage, and improved cash flow measures, positioning it well in the healthcare providers & services industry.

Income Statement

The company's income statement shows moderate financial health with a steady gross profit margin over the years. The net profit margin improved from 1.8% in 2020 to 2.8% in 2023, highlighting an upward trend in profitability. However, the revenue growth rate has been inconsistent, showing a decline in 2023 compared to 2022. The EBIT and EBITDA margins have remained stable, indicating efficient operational management.

Balance Sheet

The balance sheet reflects a strong financial position with a low debt-to-equity ratio, demonstrating prudent financial management. The equity ratio has remained stable, showcasing a solid foundation. The return on equity has improved, signifying enhanced profitability. The company's high equity base relative to its total assets suggests financial stability and lower leverage risk.

Cash Flow

Cash flow analysis reveals a positive trajectory with improved free cash flow growth, indicating better cash generation capabilities. The operating cash flow to net income ratio is robust, highlighting efficient cash management. The free cash flow to net income ratio has shown significant improvement, reflecting enhanced capability to generate cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.51B	1.60B	1.73B	1.45B	1.40B	1.36B
Gross Profit	183.15M	171.82M	202.88M	999.52M	971.62M	937.72M
EBITDA	117.26M	122.23M	116.58M	106.15M	100.21M	80.66M
Net Income	46.53M	43.35M	38.71M	25.14M	28.30M	2.46M
Balance Sheet
Total Assets	1.82B	1.86B	1.77B	1.70B	1.67B	1.63B
Cash, Cash Equivalents and Short-Term Investments	355.81M	426.66M	342.84M	304.93M	299.72M	266.15M
Total Debt	150.87M	149.60M	149.84M	158.20M	159.76M	160.60M
Total Liabilities	518.10M	530.51M	490.30M	453.51M	440.82M	439.45M
Stockholders Equity	1.27B	1.30B	1.25B	1.22B	1.20B	1.17B
Cash Flow
Free Cash Flow	32.60M	57.20M	46.20M	-16.90M	19.70M	16.30M
Operating Cash Flow	32.60M	127.60M	109.00M	41.30M	97.50M	113.30M
Investing Cash Flow	0.00	-50.40M	40.90M	-86.20M	-58.30M	-135.20M
Financing Cash Flow	0.00	-3.30M	-21.20M	-4.10M	-3.90M	-15.10M

RHON-KLINIKUM AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:RHK, the sentiment is Negative. The current price of 11.9 is below the 20-day moving average (MA) of 12.51, below the 50-day MA of 13.35, and below the 200-day MA of 13.36, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 38.62 is Neutral, neither overbought nor oversold. The STOCH value of 25.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:RHK.

RHON-KLINIKUM AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RHK	66 Neutral	€756.40M	19.73	3.09%	0.76%	12.23%	-8.23%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.34%	16.99%	1.69%
0NDG		€142.50M	5.36	12.45%	1.16%	―	―
MAK		€30.83M	―		―	―	―
LIK		€111.41M	36.37	18.60%	―	―	―
EIF		€4.47M	1.48	29.97%	―	―	―
M12	66 Neutral	€267.47M	16.52	14.61%	3.49%	7.23%	58.37%